Navigation Links
Replidyne in Medical News

Replidyne Announces Restructuring of Operations

...t by approximately 80% to 5 employees in actions that are scheduled to take place during September 2008 and October 2008. As a result of these actions replidyne will suspend further development activities of REP3123, its investigational agent for the treatment of Clostridium difficile (C. difficile) bacteria a...

Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... 1 Oral Session and 21 Poster Sessions ~ ~ replidyne Debuts New Clostridium difficile Program ~ LOUIS...pment organization," commented Kenneth J. Collins, replidyne President and CEO. "In particular, we will be pres... are essential for normal intestinal functioning. replidyne will present the following C. difficile posters on...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

...ed with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year. "REP8839 is a p...
Replidyne in Medical Technology

Replidyne Discontinues Phase III Trial

...h acute exacerbation of chronic bronchitis (AECB). replidyne took this action to conserve its cash assets and s...hree adult community respiratory tract infections. replidyne has not initiated the other three trials, and cons...ance, further faropenem development will depend on replidyne securing a partner for the program. "In the inte...

Replidyne Provides Strategic Update

... with its strategic and operations priorities, replidyne has reduced headcount by approximately 35 perc... and commercial functions. -- Pipeline programs. replidyne will retain key research and development exper...lt of prioritizing these preclinical programs, replidyne has suspended the development of topical antibioti...

Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference

... website after the event for a period of 30 days. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...-positive C. difficile bacteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-infective programs based on...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile

...hsner, Ph.D., Principal Scientist, Microbiology at replidyne during poster session 229 titled, "New Agents Acti...s novel treatment options. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...uction and spore-forming in C. difficile bacteria. replidyne is also pursuing the development of other novel an...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile

...tchley, Ph.D., Executive Director, Microbiology at replidyne during poster session 229 titled, "New Agents Acti...s novel treatment options. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...uction and spore-forming in C. difficile bacteria. replidyne is also pursuing the development of other novel an...

Replidyne Phase II Pediatric Trial Meets Primary Objective

...iatric antibiotic prescriptions for this illness. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...nd infections, including methicillin resistant S. aureus (MRSA) infections. replidyne is also pursuing the development of other novel anti-infective products bas...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

...ical antibiotic treatment. Based on these results, replidyne plans to initiate Phase II trials in children with...all impetigo treatments. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...methicillin-resistant S. aureus (MRSA) infections. replidyne is also pursuing the development of other novel an...
Replidyne in Biological Technology

Replidyne and Cardiovascular Systems Sign Merger Agreement

...e merger agreement under which CSI will merge with replidyne in an all-stock transaction. Under terms of the agreement, replidyne will issue new shares of its common stock to CSI s...ted to own 83 percent of the combined company, and replidyne shareholders are expected to own 17 percent of the...

Replidyne Announces Second Quarter 2008 Results From Operations

...cond quarter and six months ended June 30, 2008. replidyne reported a net loss of $18.7 million for the quart...basis, for the second quarter ended June 30, 2007. replidyne reported a net loss of $27.7 million for the six m...ves process." During the second quarter of 2008, replidyne announced that it had decided to terminate its lic...

Replidyne Terminates Faropenem Agreements

...or the faropenem program. As previously announced, replidyne had discontinued clinical development of faropenem...lication inhibition technology." At May 31, 2008 replidyne had cash and short term investments totaling $71.5 million. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...

Replidyne to Report First Quarter 2008 Earnings

...earnings. On Thursday, May 8, 2008 at 4:00 P.M. ET replidyne will host its annual shareholder meeting at Compan...tp://www.Replidyne.com . About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...fficile bacteria and C. difficile Infection (CDI). replidyne is pursuing the development of other novel anti-in...

Replidyne Announces 2007 Fourth Quarter and Full Year Results

...h quarter and full year ended December 31, 2007. replidyne reported a net loss of $16.9 million for the fourt...er 31, 2006. For the year ended December 31, 2007, replidyne reported net income of $7.7 million, or $0.29 per ...gnized as revenue in the period ended May 7, 2007. replidyne will not report any revenue under this agreement f...

Replidyne to Report 2007 Fourth Quarter and Year-End Earnings

...ourth quarter and year-end earnings. Additionally, replidyne will present at an upcoming investor conference in...ry 13, 2008 at 9:30 A.M. About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discover...cteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-in...

Replidyne to Announce Third Quarter 2007 Earnings

...he company's website at http://www.Replidyne.com . About Replidyne, Inc. replidyne is a biopharmaceutical company focused on discovering, developing, in-licen...-positive C. difficile bacteria and C. difficile-associated disease (CDAD). replidyne is pursuing the development of other novel anti-infective programs based on...
Other Tags
(Date:4/24/2014)... virus caused the first flu pandemic in the 21st ... killed more than 50 people in the country. Since ... epidemics (winter/spring seasons). , Infections with influenza pH1N1 ... Health Organization has recommended Tamiflu for treatment of patients ... drug is that it targets viral proteins which mutate ...
(Date:4/23/2014)... unrelated donors was safe and effective in treating ... Clostridium difficile , according to a new pilot ... and available online. Known as fecal microbiota transplantation, ... a colonoscope or a nasogastric tube. The findings ... more readily available to patients. , A growing ...
(Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
(Date:4/23/2014)... Huntington,s disease, most in their mid-thirties and forties, ... behavioral decline within two decades. "Mutant" protein clusters, ... disease, have been the primary focus of therapies ... new research from Prof. Gerardo Lederkremer and Dr. ... Cell Research and Immunology, in collaboration with Prof. ...
(Date:4/23/2014)... Valley, NY. (Apr. 23 2014) A ... neural stem cells (hNSCs) into the brains of ... after 22 and 24 months found that the ... and did not cause tumors. , The study ... Cell Transplantation but is currently freely ...
(Date:4/23/2014)... trope that the likelihood of an accurate group decision ... hold up when a collective faces a variety of ... Instead, Princeton University researchers report that smaller groups actually ... may become excessively focused on only certain pieces of ... what is known about collective intelligence, or the "wisdom ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
Other Contents